Deep Learning-Enhanced MRI Imaging for Early Alzheimer's Detection

Rashmi Ashtagi, Department of Computer Engineering, Vishwakarma Institute of Technology, Bibwewadi, Pune - 411037, Maharashtra, India, rashmiashtagi@gmail.com

Deepak Mane, Department of Computer Engineering, Vishwakarma Institute of Technology, Bibwewadi, Pune - 411037, Maharashtra, India

Bhagyashree D Shendkar, Department of Computer Science and Engineering, MIT School of Computing, MIT Art Design and Technology University, Pune, Maharashtra, India

Anant N Kaulage, MIT Art, Design and Technology University, Pune, Maharashtra, India

Sagar Mohite, Department of Computer Engineering, Bharati Vidyapeeth Deemed University college of engineering Pune - 411037, Maharashtra, India

Ranjeet Bidwe, Symbiosis Institute of Technology, Pune Campus, Symbiosis International (Deemed University) (SIU), Lavale, Pune 412115

Sangita Jaybhaye, Department of Computer Engineering, Vishwakarma Institute of Technology, Bibwewadi, Pune - 411037, Maharashtra, India

ABSTRACT

Alzheimer's disease (AD) is a chronic neurodegenerative ailment that causes numerous aberrant neural connections. As a result, patients with this crippling neurological condition have a dismal prognosis. A number of diagnostic approaches, such as MRI and deep learning methods, are currently used to determine the diagnosis of AD. However, due to the complexity of the illness and the challenge of gathering a complete collection of brain biomarkers, the accuracy of diagnosis is constrained. This study highlights the growing significance of AI-driven solutions in the medical area and acts as a crucial resource for pracademics looking to apply cutting-edge technology for diagnosis. It provides insightful information on the advantages and disadvantages of each strategy. The proposed model performance is improved by incorporating transfer learning methods into pre-trained CNN models like VGG and ResNet. The research focuses on the application of deep learning and machine learning methods as viable tools for tackling the difficulties associated with diagnosis, highlighting their potential while recognizing the necessity for a large amount of training data to attain high performance. The study is a trailblazing example of how to use genetics and sophisticated data analytic tools to improve our understanding of AD and create more individualized therapeutic strategies for this neurological condition.

KEYWORDS

Medical Image Analysis; Transfer Learning; Alzheimer's Diagnosis; Deep Learning; Neuroimaging.

INTRODUCTION

The need for an accurate and timely method of prediction has grown as the number of people with Alzheimer's disease rises. Fortunately, the application of artificial intelligence in the healthcare industry has demonstrated tremendous promise. Artificial intelligence algorithms can provide early warning indications of Alzheimer's disease, enabling pre-emptive interventions and, potentially, a more effective treatment approach. They do this by analyzing enormous volumes of data and discovering patterns that could otherwise go undetected. As a result, applying Artificial Intelligence to Alzheimer's prediction has enormous potential to enhance patient outcomes and lighten the load on healthcare systems [1].

Beginning in the grey matter, the tissue loss gradually spreads to the white matter, corpus callosum, and hippocampal region. Thus, by examining the differences in the specific structural components of the brain, the early stages of AD

can be identified and diagnosed. Mild cognitive impairment (MCI) sufferers are most likely to advance to the last stage of irreversible brain illness. MCI may be prone to both stable MCI (sMCI) and progressive MCI (pMCI) for the early prediction of AD. Normal Cognitive (NC) is the first stage of AD-related dementia, followed by sMCI, pMCI, and then AD [2].

Such machine learning algorithms must be implemented according to the proper architectural design or pre-processing procedures, which must be predefined. Four steps are often necessary for classification research utilizing machine learning: feature extraction, feature selection, dimensionality reduction, and feature-based method selection. These techniques may be time-consuming and call for specialist knowledge and several optimization stages. These methods' reproducibility has been a problem.

AD diagnosis is hard to be made precisely due to the fact that the disease is too complex for one, and there is no way to recognise a reliable biomarker. Conventional diagnostic modalities utilize MRI devices to deliver relevant analysis for the brain anatomies and diseases respectively. Among the challenges of accurately conveying events and the emotions of the characters is the fact that we need to achieve it in a consistent way. This research is based on the significance of these two challenges but also identifies the major lacks of existing AD-related datasets keeping in mind the limited availability of the comprehensive human image data. This is where the research comes into play, in which the Alzheimer MRI Pre-process Dataset is being introduced, which is a very important resource for building solutions that use AI-driven.

The CBD (Convolution Neural Network) approaches are the main analytical tools of the work, as they are applied to diagnose AD. CNNs can be correct as far as processing MRI scans as they have the best performance on the smallest image operations such as recognition and classification. The proposed way contains data preprocessing, image augmentation, model generation and evaluation. Furthermore, it serves as a structure for CNN neural network approaches to differentiate cognitive decline. However, secondly, it also looks into transfer learning methods, where a CNN model that has already been trained (like VGG and ResNet) is used as a basis for AD diagnosis, with it's extracted features guiding it to a proper finding.

The work utilizes a multitude of data sets and other resources while citing high-credibility sources, such as from reputable organizations and academic institutions, to note the said collaborative characteristic of medical studies. It helps researchers to incorporate the diversity of understanding as well as experience, which would, in the end, increase the pool of available data.

The system suggested provides the conclusions from the research, which illustrate the capacity of the AI-powered AD solution to find solutions. The CNN models know their job, which they do well as evidenced by the validation accuracy of 98.05% and a validation loss of 6.87%. A scant 25 incorrectly categorized photos out of 1280 are reported in the paper, highlighting the potential benefit of AI in improving AD diagnosis accuracy.

Additionally, the document is set up as follows: a quick review of the literature is found in section 2. The system design, methodology, and algorithms are addressed in the third section. The fourth portion discusses the dataset description, evaluation parameters, and results analysis.

LITERATURE REVIEW

Goenka et al. [3] have a prominent role in the area of medical diagnostics and studies concerned with the subject of Alzheimer's disease as well. The authors go deep into the use of deep learning techniques for MR (magnetic resonance) imaging-based AD prediction with the aim of improving early diagnosis and actuation. The work of the study is based on machine learning techniques like neural network architectures and a comprehensive collection of brain biomarkers. Therefore, it is evident that there is significant potential for the early detection of Alzheimer's using machine learning. Thus, such detection improves patient assistance and support. The study indeed points beyond the mere application of deep learning algorithms by unfolding the increased role of artificial intelligence in medical research and healthcare. This paper is primarily targeted towards researchers and experts trying to apply the best available technology in the

prediction of Alzheimer's disease; hence being a most useful reference. This article further emphasizes the potential offered by advanced AI technologies, and below are a few of the many roles that AI plays in the medical field.

Huber-Carol et al. [4] give out essential pros and cons of the survival data methodologies that are employed in combination with the machine learning approaches for the prediction of AD. The authors shed some light on the pitfalls of the prevailing methodologies compared to the blooming area of machine learning in this context. The research rigorously compares a few types of predictive models that, in turn, provide evidence of how well the latest set of machine learning algorithms perform on demanding data that have this attribute of usually being multidimensional and, thus, typical in medical research. Moreover, it brings the data-driven technique to light, which would enhance the prediction accuracy and also highly recommends the need to adopt the technique learner to the type of research the data and research objectives are based on. This piece constitutes a pertinent source of knowledge to scientists and practitioners who aim to concentrate on the mid-term between classical statistical analysis and machine learning in the scope of Alzheimer's disease prognostication, providing its adherents with crucial information regarding the pros and cons of those methods.

Kamal et al. [5], however, suggest that the AI method also needs other important inputs such as image, microarray, and explainable AI. This group of scientific studies is a great bonus to the field of dementia advancement, as they add to the knowledge about the course and predictability of Alzheimer's disease. Through a concerted use of medical image data with gene expression profiles, it facilitates a composite and multi-modal examination of patients. Adding to this, the explanation of AI approaches has led to a high level of transparency and interpretability on the predictive models, enabling a greater understanding of the linked genes that are responsible for Alzheimer's disease. This creative study represents a good example of interdisciplinary curative in the healthcare domain. What's more, it is commensurate with the integration of AI and data into which the advancement in diagnosis and management of complex neurodegenerative diseases like Alzheimer's rests. With Alzheimer's and other health conditions growing, this Alzheimer's and other related disorders article by Kamal et al. therefore has to do with respective diagnosis and treatment as it shows that this field of AI in healthcare shows on the way to enhancement providing more accuracy with diagnoses and treatment.

Wukkadada et al. [6] provide a study on ML algorithms application as a method of not just accurate prediction of Alzheimer's disease but as a tool for the better monitoring of the entire neurologic health. The unique aspect of the author's research is its significant application of machine-learning technologies to speed up the decision-making process and develop a better treatment for Alzheimer's disease. However, the authors' study differs from previous research since they consider the use of broader datasets and focus especially on KNN techniques to get more accurate predictions of AD, an attempt at the potential of data-driven methods to enhance early diagnosis, which leads to better outcomes concerning efficient treatments. This is consistent with the treatment of neurodegenerative diseases, and it is at the core of the effort to find the best ways to manage AD.

Saradhi et al. [7] demonstrate a profound insight into predicting AD in a study of this area. The reported study is about the early diagnosis of AD and uses a diagnostic MRI brain analysis procedure, particularly emphasizing the role of this technique for better patient outcomes. The proposed methodology is based upon the application of a bilateral adaptive filter (ABF) and AEO paradigm, which is used to calculate the optimal weight filters. Next, the Inception-v3 CNN model is incorporated for dividing cancer types into benign and malignant. The outlined research verified the approach's accuracy and ranked remarkably high, reaching a classification accuracy of 97.43%, a specificity score of 98.09%, a sensitivity score of 97.12%, and a very high Kappa index of 89.67%. This strategy not only performs better than other rival algorithms but also overcomes the problem of diagnosing AD, a problem that is the top concern in today's healthcare. As you see, this approach has many advantages.

Shimizu et al. [8], through the mechanism of classification and prediction of AD subtypes from genomic data, bring forward significant findings in the field of Alzheimer's aspect. The authors' research was based on the use of data from the GWAS of the Japanese population from two cohorts, and thus, the authors were able to disentangle the genetic structure of LOAD. On the basis of gene ID-CHIP, the authors distinguish two subtypes of LAD, one due to major genes (APOC1 and APOC1P1) and the other to genes related to the immune mechanism (RELB and CBLC) while the other is linked to kidney diseases (AXDND1, FBP1, and MIR2278). The remarkable association between disordered kidney function and LOAD pathogenesis brings another refresher to our consociating concepts about AD. Besides,

the scientific novelty lies in the development deep neural network model for LOAD subtypes to predict with high accuracy not only in the discovery cohort but also in the validation cohort. These findings not only shed light on the underlying mechanisms of LOAD but also illustrate the potential of genomic data and deep learning techniques to enhance our ability to classify and predict AD subtypes, ultimately advancing our grasp of this complex neurodegenerative disorder.

Rabeh et al. [9] suggested a new method of AD prediction at an early using MRI images and a combination of CNN and SVM technology. Researchers neutralize deep learning and motioning in transfer learning, which have shown their excellence in computer vision and medical image processing areas. The authors aim the development a new method that combines an adaptation of a transfer learning approach along with supporting SVM technology for the early-stage classification of AD, specifically focusing on Mild Cognitive Impairment (MCI). Using the OASIS AI Alzheimer's MRI database, which has 420 subjects (210 normal and 210 MCI), the team's model can predict the presence of this disease in an early stage with 94.88% accuracy. This is a noteworthy step towards the incorporation of the latest technology into the early diagnosis methodology of Alzheimer's, which could reduce the period of early intervention and improve the quality of life of patients fighting neurodegenerative diseases.

Nugroho et al. [10] investigate the treatment of the most alarming disease at present, which is AD, which is believed to affect thousands of people every second in the next decade. In view of the subsequently increasing number of cases, the authors are concerned with Alzheimer's disease (AD), which is the most common form of dementia, and the affected people usually have memory disorder in most cognitive functions. The study highlights that this rapidly increasing problem emphasizes the necessity for treatment, drugs, and other approaches that can help manage and prevent this devastating disease. To reinforce this, the authors attempt to develop an innovative method, a fingerprint-based ANN model that may find actual Beta-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease. To optimize the ANN architecture, the paper explores three distinct optimization strategies: Humans often have greater empathy, compassion, and emotional intelligence than machines, leading to more personalized and flexible solutions. From these, the Bat Algorithm shows a better trend with an accuracy of 0.81 and an F1-score of 0.78. These findings represent a significant step forward in leveraging computational methods to identify potential therapeutic agents for AD, offering hope for the development of effective treatments in the ongoing battle against this prevalent and devastating neurological condition.

Being cited as a source, the paper by Menagadevi et al. [11] offers a deep residual autoencoder and SVM-based automated prediction system for the detection of AD. Authors, through their study, nail down medical imaging progress and multiple means of imaging analysis of the brain from MRI to MRI, which is one of the essential stages of Alzheimer's disease diagnosis. The authors use the modified optimal curvelet thresholding and the octagonal histogram equalization intelligent method of image pre-processing with an adapter in order to boost the quality of the photos. It is the features of white matter that are next extracted from the brain images via the multi-scale pooling residual autoencoder architecture. The (SVM), (ELM) and (KNN) algorithms are used for the classification that is performed under the algorithm type. The SVM stood out with astonishing results in the Kaggle dataset and overall accuracy of 99.77% which was the highest in both of the datasets. For the ADNI dataset, the SVM also showed great results with 98.21% accuracy. This result in the field of deep learning and ML reveals the large role these techniques can play in improving AD detection and diagnosis. It is clear that there is a promising future for earlier interventions and a more accurate and timely management of this neurodegenerative condition.

Reddy Enumula and Rama Krishna Rao [12] are their part in the contemporary attempt to narrow down the specific use of necrotising data to better classify Alzheimer's disease. The investigation shows that one of the most pivotal steps for the correct diagnosis of Alzheimer's disease is the adequate usage of Machine Learning (ML) when segmenting images and performing the evaluation of the database, thus marking the necessity of advanced technologies as an essential component in this field. Importantly, VGG-16 and Improved Faster Recurrent Convolutional Neural Network (IFRCNN) methods, as they were produced before for the ImageNet database at the time the issue was studied, are brought in by the authors. The presented system proves exceptional reliability with a greater than 98 % precision on the ADNI dataset of Alzheimer's Neuroimaging Initiative. This research exemplifies the potential of machine learning and neural network-based approaches in enhancing the precision of AD prediction

and classification, offering promising avenues for early diagnosis and intervention in this complex and critical medical domain.

Ganesh et al. [13] also investigate an AI solution for the prediction of AD by employing the AI algorithms utilized in brain MRI scans. What distinguishes the work of the author is the fact that he uses three different types of CNN models named VGG-16, Inception-V3, and Xception to distinguish Alzheimer's Disease based on MRI brain scans. At the end of the relatively short training, the VGG-16 model performed the best with an accuracy of 75%, while the Xception and Inception models achieved a decision-making precision of 70%. The main task of the study is to give the possibility of capturing the process of Alzheimer's disease (no-dementia, very mild, mild, moderate) with the use of a program that can define treatment approaches given by every stage of the disease. That makes a very practical tool for more efficient treatment. Such work emphasizes the promising prospect of deep learning and AI-related technologies in the forthcoming development and management of AD, delivering evidence to patients with different present AD stages of needed personalized treatment.

Moreover, Hemalatha and Renukadevi [14] discussed the most important challenge of AD, which is destructive damage that causes memory to be loss considerably and cognitive capabilities. The authors note the insufficient capability for AD diagnosis at the early stage as one of the contributors to a high failure rate of AD drugs in clinical trials. Timely diagnosis in the course of treatment is of the highest priority; however, the picture is less clear if an individual is almost unnoticedly suffering from MCI. The study points out that besides the traditional methods used for the cognition of Alzheimer's disease, i.e., Positron Emission Tomography (PET), others could be harnessed for a better and faster perception of the disease. PET imaging plays doing great diagnostic and investigative role inside the human body, like revealing the working of the internal organs and tissues. We are striving to find appropriate features for the recognition of AD by means looking at the PET images and comparing them with different machine-learning techniques that we will use to help with diagnosis. Notably, the study delves into the use of Artificial Neural Networks and deep learning techniques as promising tools for addressing AD diagnostic challenges, emphasizing the potential of these approaches while acknowledging the need for substantial training data to achieve high performance. This work contributes to the ongoing efforts to enhance early diagnosis and intervention in AD, a crucial area in neurodegenerative disorder research.

Humpfal et al. [15] provide a very remarkable way of honing in on the issue of finding an effective treatment for AD. They highlight the first genome-wide exploration of biomarkers associated with therapeutic response in AD, accomplishing it by focusing on the investigation of Blarcamesine (ANAVEX2-73) in Phase 2a clinical trial of the behavior. The study involves a 57-week period, as 208 weeks are dedicated to long-term monitoring in the hope of gaining more profound insights into the nature of AD. The authors develop a precision medicine model based on AI function, namely unsupervised formal concept analysis (FCA) through integration into the Knowledge Extraction and Management (KEM) module, to elucidate the mechanism between the patient data and outcomes. In this study, the authors report six biomarkers, including the mean level of plasma concentration of blarcamesine and specific genomic variants that have a strong correlation with the outcome of the changes in cognitive and functional assessments. This being the case, data on neurodegenerative markers in AD have the potential to be used in the personalization of the treatment in AD, and early phase IIb and III clinical trials attempt to determine the significance of these markers in informing treatment. This contribution is grounded in using data mining methods and genomics rather than just statistically oriented analyses to gain more in-depth knowledge about AD and to develop different personalized approaches for treating this difficult form of neurodegeneration.

Rashmi Patil & Sreepathi Taylor disclosed a cutting-edge application in the field of melanoma cancer detection [16]. As melanoma is one of the most vicious and fatal shapes of common skin cancer, exact staging has an integral role in the determination of an effective treatment plan. This study is based on models implementing the use of Convolutional Neural Networks (CNNs) and a novel loss function called Similarity Measure for Text Processing (SMTP) to determine the stages of melanoma cancer. Their findings from the experiment help indicate that the SMTP loss function works better than generic loss functions, thusly exhibiting the system's efficiency and accuracy of melanoma staging.

Through the lens of Rashmi Patil's [17] research on melanoma, she illustrates spotting malignant melanoma, a kind of skin cancer and emphasizes the importance of early detection. The investigation emphasizes the difficulty of discerning melanoma cases from non-carcinoma cases and brings in dermoscopy as one such skill that can be employed for the assessment of skin lesions. What the research proposes is a new type of approach which's success is a result of a combined use of CNN and ML methods such as SVM (support vector machines) and XGB (XGBoost). CNNs are a crucial part of the suggested system because they have a proven track record of performance in object recognition. In general, the research investigates how machine learning might improve melanoma detection precision and automate the diagnosis procedure. In [18], transfer learning is used to detect type of cancer.

The literature review underscores several limitations and opportunities for further research in the field of AD prediction, classification, and treatment strategies. A common challenge identified in many of these studies pertains to the availability and size of the datasets used. Both machine learning (ML) and deep learning algorithms intensively depend on huge and diverse data, but the challenge in acquiring data for AD research is itself complex. In addition, it remains to be seen whether bias can be avoided by relying solely on datasets that are only representative of the population at large, which raises a new issue. In order to resolve this issue, a better way would be through calling for joint efforts by research institutions and the collection and exchange of much more complete and insightful data. Besides, anonymization of the data and its standardization for use in sharing with other institutions has to be prioritized to strike a balance between sharing data and upholding privacy. Similar methods like data enhancement and transfer learning may be put into practice to enable the proposed system to obtain the utmost use out of the limited set of data. In doing so, it will attain better generalization and robustness.

Moreover, the researcher pointed out the issue of interpreting and explicability of machine learning and deep learning models in the same research work. Whereas such models can frequently show high performance, their inconceivable decision-making process escapes understanding, especially in the clinical practice domain, where interpretability is very important. Our proposed research regarding Alzheimer's disease prediction aims to increase the ability of models to explain themselves by improving the specificity of the techniques that are being employed. This condition not only facilitates the AI-advent but also generates important information on the structure of Alzheimer's disease and brings more precision to the treatment strategies. Moreover, when the question of the ethical consequences of AI in the healthcare sector is posed, this also means the necessity of the creation of ethical principles and standards for the proper and safe use of intelligent automation systems. These guidelines should be mainly based on transparency and publicity to lay down the ethical practices concerning artificial intelligence in the in-healthcare sector.

PROPOSED SYSTEM

The investigational system had a detailed methodology sufficient to adhere to the needs of patients, doctors, and scientists. From user registration and authentication, which the system will need to make sure is done securely while also giving the users privacy of access and data, the system will move to locations and tours. There would be a possibility for users to create and revise their data pro dialogs periodically, while entering their personal information and medical histories initially. The diagram of the system architecture 1 below explicates the conceptual model.

The suggested system's natural detection mechanism based on AI is the root that makes the system work. The trained Convolutional Neural Network (CNN) model would provide an immediate and precise outcome following the uploaded MRI scans that indicate AD using prompt. The user's comprehensibility can be enhanced by ensuring the system offers explanations of the findings in language laymen can quickly understand, leading to the understanding of an insight into the meaning of findings and perhaps the subsequent procedures.

The system's simplicity of input of data was one of its key benefits, and users could import MRI images from their devices straight into the system without any effort. The intuitive interface renders the image loading and capturing to be simple. The program was set up in such a way as to ensure that all photos were selected automatically so as to check that they fulfilled the required quality and format specifications before any analysis.

Figure 1: System Architecture Diagram

A. CNN Model:

The crucial deep learning record for the interpretation of the magnetic resonance imaging (MRI) scans of brain to detect Alzheimer's disease is the convolutional neural nets (CNNs). Modification of CNN networks through transfer learning principles is the core method in the study. The models of well-known architecture like VGG and ResNet are used for the task of Alzheimer's disease recognition. The Alzheimer MRI dataset, as a critical exercise, assists us in training and refining these algorithms to be more accurate in differentiating Alzheimer's MRI images with and without indications of Alzheimer's disease. Where model performance is estimated using parameters like accuracy and validation loss measures are demonstrated. Finally, CNNs take the place in the sphere of AD diagnosis improvement with their high level of accuracy and reliability, calling to mind their importance for medical image analysis and clinical practice.

B. Four different classes make up the dataset that was used:

Mildly Demented (Class 1): People in this class have Alzheimer's disease-related minor cognitive impairment. Although their symptoms are not yet severe, these people may have memory loss, trouble solving problems, and other cognitive difficulties.

Moderately demented (Class 2): members who have advanced to a moderate degree of Alzheimer's disease. Their cognitive impairments are more severe, affecting day-to-day functions and accelerating memory loss and cognitive decline.

Non-Dementia (Class 3): People in this category do not show any symptoms of dementia or cognitive impairment. They are regarded as cognitively healthy and do not exhibit Alzheimer's disease signs.

Very Mild Demented (Class 4): Also known as "very mild" or "early-stage" dementia, this class includes those who are experiencing the first symptoms of AD. Cognitive impairments are typically less severe than in moderate or severe phases, and symptoms can be modest.

To effectively categorize MRI scans and recognize people with Alzheimer's disease or those at risk, machine learning models must be trained and evaluated with the help of these class labels. The stratification of the information into these classes enables a thorough evaluation of the performance of the AI-based detection system at various disease phases.

C.   Training and Testing

A particular task of detection and classification of Alzheimer's that requires the cooperation of the Convolutional Neural Network (CNN) model has been intensely created and trained for the course of this research. First, the system will import all necessary libraries and ensure that GPUs are being used effectively during training, which involves benefiting from the maximum benefits of TensorFlow and Keras by their nature. One crucial part of the data preparation in the mentioned study with respect to Alzheimer's is the careful division of the Alzheimer's dataset into the training and validation parts. The labels of the classes have been taken from the dataset hence, the data sets show how these information subsets help the learning model to differentiate between various stages or types of Alzheimer's disease.

Proposed system performance guides the choice of optimization methods usually, it is Adam optimizer and categorical cross-entropy loss function, also. At the initial stage of training some methods like stopping early and test rate decreasing are used with the aim to prevent the model from overfitting. The performance of the model is rigorously hyped, and the visual observations of the performance during the training process are generated through some measurement parameters such as accuracy and loss. In the end, a detailed confusion matrix, misclassified image presentation, and the testing of the model on the validation sample are fully pictured by the model's achievements in predicting Alzheimer's disease. The results of these studies may be able to produce the input in the medical image analysis and Alzheimer's disease diagnosis sectors.

D.   Algorithm of the proposed system:

Step 1: start

Step 2: Load the Alzheimer MRI Preprocessed Dataset

Step 3: Split the dataset into training, validation, and test sets

Step 4: Data Augmentation

Step 5: Define CNN Architecture

Step 6: Compile the Model

Step 7: Model Training

Step 8: Transfer Learning

Step 9: Load a pre-trained model (e.g., VGG or ResNet)

Step 10: Modify the model architecture for the Alzheimer's detection task

Step 11: Fine-tune the model on the Alzheimer's dataset

Step 12: End Results

METHODOLOGY

In the following, we explained the whole "How CNN was used for detection of AD- a comprehensive approach" methodology. The methodology covers processing of the data used, model architecture choice, training, validation, transfer learning explorations, as well as investigation of the misclassification.

1.   Data Preparation:
a)   Data Collection:

One of the first steps that we have taken in our research was to download the Alzheimer MRI preprocessed dataset, which is a collection of MR images (magnetic resonance imaging) that have been previously processed. The 6400 MRI scans in this dataset are divided into four categories: senile dementia, dementia of moderate stage, no dementia, and very mild dementia. To ensure a broad representation and fullness, we collected this information from different places such as websites, clinics, and public libraries.

b)   Data preprocessing:

Strict preprocessing was carried out before model training. To standardize inputs, all photos were scaled evenly to 128 × 128 pixels. To improve model robustness and generalization, normalization and data augmentation approaches were also used.

2.   Model Selection:

CNN Architectures:

While there are many choices out there, choosing our CNN architecture was an essential step in this process. As such, our work encompasses the exploration and implementation of the top picture classification networks, as in the case of VGG, ResNet, and Inception, which have been proven to be effective. The layout and the devices made the environment of our tests. Also, it was the medium that we used to compare the performance.

3.   Model Training and Evaluation:

Configuration for training: For our CNN models, we use Python 3. x along with TensorFlow and Keras configurations. We employed a learning rate scheduler, a categorical cross-entropy loss function as well as Adam optimizer throughout the training. Training and validation sets were created from the dataset as a machine learning model was being trained in search of its effective usage.

The model reached a certain level of performance after a set number of epochs, followed by a benchmark. Classification metrics and training and validation loss were counted in each epoch. To figure out the model`s real-world applicability, the results of model tests were analyzed on a separate test set.

4.   Transfer Learning Exploration:

We took a step forward toward creating a study that transferred pre-trained CNN model learning. Moreover, we found that transfer learning had a lot to offer. Although the original frameworks used in both cases were VGG and ResNet, they are evolving, practically stealing ideas of donor networks. Pre-trained model performance was evaluated using the collection developed and compared with models where transfer learning was not considered.

5.   Class-Specific Accuracy:

To understand how the CNN models performed differently, we examined their accuracy for various stages of dementia. We were able to determine whether certain models were particularly good at spotting particular stages of dementia by calculating class-specific accuracy for each class.

6.   Misclassification Analysis:

A rigorous investigation of misclassification determined the classes that were more prone to misclassification. For each class, misclassified photos were recorded, highlighting potential areas for model performance improvement.

7.   Ethical Considerations:

Our study models represent the data security and the privacy of the end-users by incorporating the performance of ethical standards. Patient privacy is ultimately the most prominent consideration here; hence all PII were stripped either through identifying and deleting identifiable information or anonymizing it. To prohibit unauthorized access to sensitive medical data, we employed secure data streaming and access device locking.

8.   Statistical Analysis:

To ensure the reliability of our findings, statistical significance tests like t-tests and ANOVA were used to determine the significance of observed differences in model performance.

9.   Visualization:

To ensure that the public, as well as officials, may comprehend the results, the results of our research were presented with the assistance of visualization methods utilizing different representations of data including tables, line charts, bar graphs, and radar maps.

This comprehensive methodology that is outlined here details the way we went about research and involves data preprocessing, model choice, training, evaluation, transfer learning investigation, class-specific accuracy changes, misclassification analysis, ethical considerations, statistical analysis, and visualization procedures. These decisions affirmed that our AI-based Alzheimer's Disease Detection was made to ensure rigorous and valid research.

Loss Function (L): For a certain sample or batch of data, the loss function measures the discrepancy between the model's predictions ($\hat{y}_i$) and the actual labels (y). A typical loss function for multi-class classification problems, such as Alzheimer's disease detection, is categorical cross-entropy:

$$L(y,\hat{y}) = -\sum_{i=1}^{N} y_1 \, log(\hat{y}_i)$$

Here, N is the number of classes, y_i is the true label for class i, and $\hat{y}_i$ is the predicted probability for class i after passing through a SoftMax activation function.

Technologies Used:

•   **Python 3.x:** The primary programming language used for developing and implementing machine learning models and data processing.

•   **TensorFlow:** A deep learning framework for building and training neural networks, crucial for developing and evaluating Convolutional Neural Networks (CNNs).

•   **Keras:** A high-level neural networks API (integrated with TensorFlow) that simplifies the development of deep learning models, including CNNs.

•   **Seaborn:** A data visualization library used for creating informative and visually appealing plots and graphs.

•   **Scikit-learn:** An ML library that provides essential tools for data preprocessing, model selection, and evaluation.

•   **Scikit-image:** An image processing library integrated with scikit-learn, used for image-related tasks and preprocessing.

- **Pydot and Graphviz:** Tools for creating and visualizing neural network architectures and decision trees, respectively.

- **Kaggle Dataset:** The dataset obtained from Kaggle, a well-known platform for machine learning datasets and competitions, is used as the primary data source for Alzheimer's disease detection.

- **CUDA Toolkit:** A GPU-accelerated computing platform used for faster training of deep learning models on compatible hardware.

These technologies collectively support the development, training, and evaluation of ML models for AD detection, ensuring efficient data processing, model training, and visualization of results.

RESULT DISCUSSION

A. Overview of the Dataset:

The dataset is a collection of MRI pictures that have been previously processed and specially shrunk to a resolution of 128 by 128 pixels. With the main goal of facilitating the design and development of precise classification frameworks for AD, it has been curated from a variety of sources, including websites, hospitals, and public archives [19].

TABLE: Dataset Class Labels Summary

Class Label	Description	Number of Images
Class 1: Mild Demented	Mild stage of Alzheimer's disease	896
Class 2: Moderate Demented	Mild stage of Alzheimer's disease	64
Class 3: Non-Demented	No signs of Alzheimer's disease	3200
Class 4: Very Mild Demented	Very mild stage of Alzheimer's disease	2240

B. Evaluation Metrics:

The evaluation model employs the confusion matrix. It is shown as a table that details how well a classification model performed on a set of test data in ML. The performance of the proposed work is assessed using accuracy, recall, precision, and the F1 score. Measures are determined by:

$$Accuracy = \frac{Tp + Tn}{Tp + Tn + Fp + Fn}$$

$$Precision = \frac{Tp}{Tp + Fp}$$

$$Recall = \frac{Tp}{Tp + Tn}$$

$$F1 = 2 \times \frac{Precision \times Recall}{Precision + Recall}$$

where, T_p, F_p, F_n, T_n represent true positive, false positive, false negative, and true negative.

C. Result Analysis:

CNNs are being used in the proposed method to construct ML models for the identification of AD. Python 3.x, TensorFlow, Keras, Seaborn, scikit-learn, scikit-image, Pydot, and Graph viz for GPU training, as well as CUDA Toolkit, were used in the construction of this system.

The figure 3 below shows the training data input sample for the proposed model.

Figure 3: Trained Data Sample

The "Alzheimer MRI Preprocessed Dataset," which consisted of images reduced to 128 × 128 pixels and sourced from various websites, hospitals, and public repositories, served as the centerpiece of the proposed system. The four unique groups that make up this dataset—"Mild Demented" (896 images), "Moderate Demented" (64 images), "non-demented" (3200 images), and "Very Mild Demented" (2240 images)—represent the various stages of dementia. The effectiveness of these models at detecting Alzheimer's disease and the training progress of the model from 0 to 16 epochs are shown in the following graphs (Figure 4).


Figure 4: Model Training History

The intended purpose of the proposed approach was to make it easier to create and develop a precise framework or architecture for the classification of AD. It made referrals to other sources of information and study about AD, thus enhancing the resources already available.

The implementation of the code, which included data preparation, picture enhancement, model construction, and evaluation using CNNs, served as the system's central component. Transfer learning methods with pre-trained models like VGG and ResNet were investigated. The CNN models were constructed using TensorFlow's Keras API. The figure 5 below shows the validated training data output of the proposed model.

Figure 5: Validated Data Output

Our results indicate that the proposed model architecture outperforms the other models, achieving the highest accuracy of 98.05% and the validation loss of 0.68. There were 25 misclassified photos out of 1280. For researchers and practitioners in the area, the suggested approach offered a thorough framework for the creation and assessment of ML models for AD diagnosis utilizing CNNs. Figure 6 and Figure 7 below explain the confusion matrix of the proposed system classifier over different classes and the bar graph of model comparison with accuracy and validation loss of VGG and ResNet, respectively.


Figure 6: Confusion Matrix of the Classifier

Figure 7: Model Comparison Bar Graph

Figure 8: Proposed System Error Plotting

D.   Test Cases:

The specifics of the test cases created for the proposed system are highlighted in this section. The test cases and outcomes for data preprocessing, compatibility and performance testing are shown in Tables I, and II, respectively.

TABLE: Data Preprocessing Test Cases

Functionality	Result
Verify that the dataset is correctly loaded and contains the expected number of images for each class.	Passed

Check the success of data augmentation techniques, ensuring the creation of diverse training samples.	Passed
Validate the resizing process, confirming that all images are resized to 128x128 pixels.	Passed

TABLE 2: Model Creation and Training Test Cases

Performance	Result
Train a CNN model using the provided code and dataset, ensuring convergence and successful model creation.	Passed
Test different CNN architectures, such as VGG and ResNet, using transfer learning and verify their performance.	Passed
Check for overfitting by comparing training and validation loss curves.	Passed

We trained and assessed models utilizing designs including VGG, ResNet, proposed model in order to compare the performance of different CNN architectures.

E.   Class-Specific Accuracy and Misclassification Analysis:

We looked at the models' accuracy for different stages of dementia to see if they performed better for certain classes, and we ran a misclassification analysis to see which stages of dementia are more likely to be misclassified. The number of images that were improperly classified for each class and the top model's accuracy in each category are displayed in the table below:

Dementia Class	Accuracy	Misclassified Images
Mild Demented	94.50%	22
Moderate Demented	93.20%	33
Non-Demented	98.05%	15
Very Mild Demented	92.70%	28

Our results indicate that the model excels in accurately detecting the "non-demented" class with the highest accuracy of 98.7% and the "Moderate Demented" class has the greatest amount of incorrectly identified photos, necessitating more research into how to increase this class's classification accuracy.

These findings show how effective CNN models—in particular, ResNet with transfer learning—can be in accurately diagnosing Alzheimer's disease. Our results highlight the value of transfer learning and architecture selection in improving model performance and urge further study to solve issues with class-specific accuracy and misclassification rates.

CONCLUSION

This study has been designed for a smooth operation of the Convolutional Neural Networks for Alzheimer's disease diagnosis. Our research addressed pre-processing of the data, image augmentations, construction, and assessment of CNN models, particularly models using pre-trained networks like the VGG and the ResNet, on the Alzheimer MRI Preprocessed Dataset that consists of 6400 MRI images allocated into four classes according to the disease stage severity. The results illustrate that CNNs for AD classification applications have a great future, as a robust network with an accuracy of 98.05% and a loss of 6.87% was used for the validation. The model's robustness is highlighted by its accuracy, where it only classifies 25 out of 1280 images incorrectly. The demonstrated method is a great starting point for the researchers and appropriate practitioners. It can also be a milestone on which scientists can further improve the development of machine learning in AD diagnosis. The main goal of this research work is to whether it is proven to be beneficial greatly to the patient treatment of AD or not.

FUTURESCOPE

CNNs have the future of possibility to deliver en masse to the newest AD detection technologies. The proposed mechanism is seen as the first reason for the development of early diagnosis and intervention, which the groundings will be important to the later advancement. The development of CNNs with architectures that are sophisticated even more and the incorporation of the image processing philosophy into their models may lead to precisely precise models that are also accurate. On the other hand approach with considerable datasets can contribute to model robustness and its capacity to be generalized. Hence, they can be applied in real clinical settings. Using multimodal information,

which can be MRI scans and patient backgrounds, the full picture of how AD progresses may be formed so that more reliable prognoses and personalized treatment protocols can be accomplished. On the other hand, the implementation of interpretability notions and explainable AI can be beneficial for reducing the concealing of the operation of these models, which in turn increases the credibility of practitioners and patients. Collaborations between specialists from radiology, neurology, or machine learning fields are among the anticipated innovators, which should lead to effective tools for timely AD early detection and better management, which would ultimately result in better care for patient health. The amalgamation of knowledge in medicine and technology holds the opportunity for much more fantastic development in the Alzheimer's fighting process.

REFERENCES

1. https://www.alzheimers.net/
2. Bae, J.B., Lee, S., Jung, W. et al. Identification of Alzheimer's disease using a convolutional neural network model based on T1-weighted magnetic resonance imaging. Sci Rep 10, 22252 (2020). https://doi.org/10.1038/s41598-020-79243-9
3. Goenka, Nitika, and Shamik Tiwari. "Deep learning for Alzheimer prediction using brain biomarkers." Artificial Intelligence Review 54, no. 7 (2021): 4827-4871.
4. Huber-Carol, Catherine, Shulamith Gross, and Filia Vonta. "Risk analysis: survival data analysis vs. machine learning. application to alzheimer prediction." Comptes Rendus Mecanique 347, no. 11 (2019): 817-830.
5. Kamal, Md Sarwar, Aden Northcote, Linkon Chowdhury, Nilanjan Dey, Rubén González Crespo, and Enrique Herrera-Viedma. "Alzheimer's patient analysis using image and gene expression data and explainable-AI to present associated genes." IEEE Transactions on Instrumentation and Measurement 70 (2021): 1-7.
6. Wukkadada, Bharati, Kirti Wankhede, Sangeetha Rajesh, C. Ria, and Tridib Chakraborty. "Alzheimer Prediction using Machine Learning Algorithm." In 2023 Somaiya International Conference on Technology and Information Management (SICTIM), pp. 39-43. IEEE, 2023.
7. Saradhi, MV Vijaya, Pinagadi Venkateswara Rao, V. Gokula Krishnan, K. Sathyamoorthy, and V. Vijayaraja. "Prediction of Alzheimer's Disease using LeNet-CNN model with Optimal Adaptive Bilateral Filtering." International Journal of Communication Networks and Information Security 15, no. 1 (2023): 52-58.
8. Shigemizu, Daichi, Shintaro Akiyama, Mutsumi Suganuma, Motoki Furutani, Akiko Yamakawa, Yukiko Nakano, Kouichi Ozaki, and Shumpei Niida. "Classification and deep-learning–based prediction of Alzheimer disease subtypes by using genomic data." Translational Psychiatry 13, no. 1 (2023): 232.
9. Rabeh, Amira Ben, Faouzi Benzarti, and Hamid Amiri. "CNN-SVM for prediction Alzheimer disease in early step." In 2023 International Conference on Control, Automation and Diagnosis (ICCAD), pp. 1-6. IEEE, 2023.
10. Nugroho, Aldiyan Farhan, Reza Rendian Septiawan, and Isman Kurniawan. "Prediction of Human β-secretase 1 (BACE-1) Inhibitors for Alzheimer Therapeutic Agent by Using Fingerprint-based Neural Network Optimized by Bat Algorithm." In 2023 International Conference on Computer Science, Information Technology and Engineering (ICCoSITE), pp. 257-261. IEEE, 2023.
11. Menagadevi, M., S. Mangai, Nirmala Madian, and D. Thiyagarajan. "Automated prediction system for Alzheimer detection based on deep residual autoencoder and support vector machine." Optik 272 (2023): 170212.
12. Reddy Enumula, Raveendra, and Rama KRISHNA RAO. "Alzheimer's disease prediction and classification using CT images through machine learning." Bratislava Medical Journal/Bratislavske Lekarske Listy 124, no. 5 (2023).
13. Ganesh, C. HSCA Rama, G. Sri Nithin, S. Akshay, and T. Venkat Narayana Rao. "Multi class Alzheimer disease detection using deep learning techniques." In 2022 International Conference on Decision Aid Sciences and Applications (DASA), pp. 470-474. IEEE, 2022.
14. Hemalatha, B., and M. Renukadevi. "Analysis of alzheimer disease prediction using machine learning techniques." Information Technology In Industry 9, no. 1 (2021): 519-525.
15. Hampel, Harald, Coralie Williams, Adrien Etcheto, Federico Goodsaid, Frédéric Parmentier, Jean Sallantin, Walter E. Kaufmann, Christopher U. Missling, and Mohammad Afshar. "A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study." Alzheimer's & Dementia: Translational Research & Clinical Interventions 6, no. 1 (2020): e12013.
16. Patil, Rashmi, and Sreepathi Bellary. "Machine learning approach in melanoma cancer stage detection." *Journal of King Saud University-Computer and Information Sciences* 34, no. 6 (2022): 3285-3293.

17. Patil, Rashmi et al., "Machine learning approach for malignant melanoma classification." *International Journal of Science, Technology, Engineering and Management-A VTU Publication* 3, no. 1 (2021): 40-46.

18. Mane, D., Ashtagi, R., Kumbharkar, P., Kadam, S., Salunkhe, D., Upadhye, G. (2022). An improved transfer learning approach for classification of types of cancer. Traitement du Signal, Vol. 39, No. 6, pp. 2095-2101. https://doi.org/10.18280/ts.390622

19. https://www.kaggle.com/datasets/sachinkumar413/alzheimer-mri-dataset